Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

Immune checkpoint inhibitors are a standard therapy in metastatic urothelial carcinoma (UC). Long-term follow-up is necessary to confirm durability of response and identify further safety concerns. In KEYNOTE-045, patients with metastatic UC that progressed on platinum-containing chemotherapy were r...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2023-03, Vol.34 (3), p.289-299
Hauptverfasser:	Balar, A.V., Castellano, D.E., Grivas, P., Vaughn, D.J., Powles, T., Vuky, J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N.J., Climent, M.A., Necchi, A., Petrylak, D.P., Plimack, E.R., Xu, J.Z., Imai, K., Moreno, B.H., Bellmunt, J., de Wit, R., O’Donnell, P.H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Transitional Cell - drug therapy Cisplatin - therapeutic use cisplatin resistant/refractory cisplatin-ineligible Follow-Up Studies Humans pembrolizumab Urinary Bladder Neoplasms - drug therapy urothelial carcinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!